Sarah P Hammond
Overview
Explore the profile of Sarah P Hammond including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Phan T, Ribeiro R, Edelstein G, Boucau J, Uddin R, Marino C, et al.
J Virol
. 2025 Feb;
:e0162324.
PMID: 39902924
Importance: Nirmatrelvir-ritonavir is an effective treatment for SARS-CoV-2. In a subset of individuals treated with nirmatrelvir-ritonavir, the initial reduction in viral load is followed by viral rebound once treatment is...
2.
Kakoullis L, Alonso C, Burns R, Aleissa M, Haddad E, Kim A, et al.
Clin Infect Dis
. 2025 Jan;
PMID: 39873391
Background: Babesiosis poses significant risks of adverse outcomes in individuals with immunocompromising conditions (IC) and asplenia/hyposplenia (AH). This study compares clinical outcomes between these vulnerable groups and immunocompetent patients. Methods:...
3.
Phan T, Ribeiro R, Edelstein G, Boucau J, Uddin R, Marino C, et al.
bioRxiv
. 2024 Sep;
PMID: 39345409
In a subset of SARS-CoV-2 infected individuals treated with the oral antiviral nirmatrelvir-ritonavir, the virus rebounds following treatment. The mechanisms driving this rebound are not well understood. We used a...
4.
5.
Little J, Kampouri E, Friedman D, McCarty T, Thompson 3rd G, Kontoyiannis D, et al.
Open Forum Infect Dis
. 2024 Jun;
11(6):ofae133.
PMID: 38887472
Chimeric antigen receptor (CAR) T-cell therapy is a novel immunotherapy approved for the treatment of hematologic malignancies. This therapy leads to a variety of immunologic deficits that could place patients...
6.
Young J, Andes D, Ardura M, Arrieta A, Bow E, Chandrasekar P, et al.
Open Forum Infect Dis
. 2024 Mar;
11(3):ofae082.
PMID: 38481428
The epidemiology of invasive aspergillosis (IA) is evolving. To define the patient groups who will most likely benefit from primary or secondary prophylaxis, particularly those whose medical conditions and IA...
7.
Monk M, Patel N, Elshaboury R, Kubiak D, Hammond S
Open Forum Infect Dis
. 2024 Mar;
11(3):ofae063.
PMID: 38449919
commonly causes bloodstream infections (BSIs) in neutropenic patients but infrequently results in infective endocarditis (IE) in this population. Among 210 patients with neutropenia and BSI, 55% underwent cardiac imaging. None...
8.
Hammond S, Rangaraju M, Sumner M, Timmler B, Chandrasekar P, Avery R
Open Forum Infect Dis
. 2024 Mar;
11(3):ofae046.
PMID: 38444818
Background: Acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infection is an uncommon problem typically seen in immunocompromised hosts. Systemic treatment options are limited. The performance of foscarnet and its toxicities in...
9.
Hammond S, Little J
Clin Infect Dis
. 2024 Feb;
79(5):1318-1319.
PMID: 38307033
No abstract available.
10.
Li Y, Choudhary M, Regan J, Boucau J, Nathan A, Speidel T, et al.
Sci Transl Med
. 2024 Jan;
16(731):eadk1599.
PMID: 38266109
Despite vaccination and antiviral therapies, immunocompromised individuals are at risk for prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but the immune defects that predispose an individual to persistent...